The anti-Candida activity of Thymbra capitata essential oil: effect upon pre-formed biofilm |
| |
Authors: | Palmeira-de-Oliveira A Gaspar C Palmeira-de-Oliveira R Silva-Dias A Salgueiro L Cavaleiro C Pina-Vaz C Martinez-de-Oliveira J Queiroz J A Rodrigues A G |
| |
Affiliation: | 1. CICS-UBI, Health Sciences Research Center, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal;2. Department of Microbiology, Faculty of Medicine, University of Porto, Porto, Portugal;3. Cardiovascular Research &; Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal;4. Centre of Pharmaceutical Studies, Faculty of Pharmacy, University of Coimbra, Portugal;5. Women and Child Health Department, Hospital Center of Cova da Beira, Covilhã, Portugal |
| |
Abstract: | Ethopharmacological relevanceThymbra capitata essential oil is traditionally considered to exhibit powerful antiseptic properties, thus being used to treat cutaneous infections. The aim of the present study was to evaluate the effect of Thymbra capitata essential oil upon pre-formed biofilm of different Candida strains while comparing it with the activity against planktonic cells.Materials and methodsFifteen Candida isolates were included, corresponding to clinical and collection type strains. Essential oil was obtained by hydrodistillation and its composition analysed by GC/MS. Activity upon planktonic cells was evaluated according to M27-A3 macromethod. Its effect upon 24 h preformed biofilm biomass was determined using the crystal violet procedure and the metabolic activity was studied applying the XTT/menadione technique.ResultsBiofilm biomass and metabolic activity of all tested species were reduced up to 50% at MIC values. The effect was more pronounced at double MIC values, achieving >80% reduction, except for Candida albicans that presented a more resistant profile (62%).ConclusionThymbra capitata essential oil presented an important effect upon Candida biofilms. It is proposed as a valuable antifungal product to be used in an appropriate pharmaceutical formulation for the management of resistant mucocutaneous candidosis. |
| |
Keywords: | BHI, brain heart infusion CLSI, Clinical Laboratory Standard Institute CV, crystal violet DMSO, dimethyl sulfoxide EO, essential oil GC, gas chromatography GC/MS, gas chromatography/mass spectrometry MIC, minimal inhibitory concentration MLC, minimal lethal concentration MOPS, 3-(N-morpholino) propanesulfonic acid RVVC, recurrent vulvovaginal candidosis YPD, yeast potato dextrose broth SDA, sabouraud agar VVC, vulvovaginal candidosis XTT, 2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|